A clinical case of cystic fibrosis patient with pathogenic N1303K genotype variant with assessment of the CFTR channel function by intestinal current measurement and forskolin-induced swelling in rectal organoids

Cover Page

Cite item

Abstract

Rationale: Cystic fibrosis is a common monogenic disease related to pathogenic nucleotide sequence variants in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) (ABCC7) gene. The CFTR gene consists of 27 exons and is located in the 31.1 region on the long arm of chromosome 7 (7q31.1). The use of the sequencing method has led to the accumulation of new information about the diversity of genetic variants in cystic fibrosis. This information is important considering approaches to the development of targeted therapy for the disease, based on an individual genotype. No targeted therapy has been developed for the N1303K class II genetic variant. The function of the chloride channel in this mutation has not been compared with that in class II mutations like F508del.

Materials and methods: We have analyzed medical files of a patient with cystic fibrosis and F508del/N1303K CFTR genotypes, including the results of rectal biopsy samples. The assessments included measurement of the intestinal potential difference and forskolin-induced swelling assay (FIS) in rectal organoids, with the results being analyzed in relation to the clinical data.

Results: The results of intestinal current measurements (ICM) confirm that the N1303K genetic variant is “severe” and leads to the loss of the working CFTR protein, which is consistent with the clinical manifestations. The mean short circuit currency density (ΔISC) in response to amiloride (sodium channel stimulation) was -39 ± 1.22 µA/cm2, to forskolin (chloride channel stimulation) 3.83 ± 1.43 µA/cm2, to carbachol 6 ± 2.47 µA/cm2, and to histamine 8.5 ± 3.02 µA/cm2.

FIS results indicate that the VX-770 potentiator and the VX-809 corrector have a weak effect on the stimulation of organoids by forskolin in the genetic variant N1303K: organoid swelling was non-significant (about 20% from their baseline size).

Conclusion: The use of the ICM method and FIS assay in human intestinal organoids makes it possible to quantify the work of the CFTR protein and determine the in vitro effectiveness of targeted therapy in patients with cystic fibrosis. CFTR modulators are ineffective in patients with N1303K mutation in the compound-heterozygous condition with F508del, despite both pathogenic variants belong to class II.

About the authors

E. I. Kondratyeva

Research Centre for Medical Genetics

Author for correspondence.
Email: elenafpk@mail.ru
ORCID iD: 0000-0001-6395-0407

Elena I. Kondratyeva - MD, PhD, Professor, Head of Scientific and Clinical Department of Cystic Fibrosis, Chief of Chair of Respiratory System Diseases Genetics, Institute of Higher and Additional Professional Education; Pediatrician, Department of Cystic Fibrosis.

1 Moskvorech'e ul., Moscow, 115522.

Russian Federation

N. D. Odinaeva

Children's Clinical Multidisciplinary Center of the Moscow Region

Email: info@mokdcd.ru
ORCID iD: 0000-0001-5214-8072

Niso D. Odinaeva - MD, PhD, Professor, Chief Physician.

62 Bol'shaya Serpukhovskaya ul., Moscow, 115093.

Russian Federation

V. D. Sherman

Research Centre for Medical Genetics

Email: tovika@yandex.ru
ORCID iD: 0000-0003-2206-1528

Victoria D. Sherman - MD, PhD, Leading Research Fellow, Scientific and Clinical Department of Cystic Fibrosis; Associate Professor, Chair of Respiratory System Diseases Genetics, Institute of Higher and Additional Professional Education.

1 Moskvorech'e ul., Moscow, 115522.

Russian Federation

A. S. Efremova

Research Centre for Medical Genetics

Email: anna.efremova.83@gmail.com
ORCID iD: 0000-0001-5035-6396

Anna S. Efremova - PhD (in Biol.), Senior Research Fellow, Laboratory of Stem Cell Genetics.

1 Moskvorech'e ul., Moscow, 115522.

Russian Federation

Yu. L. Melyanovskaya

Research Centre for Medical Genetics

Email: melcat@mail.ru
ORCID iD: 0000-0002-8814-5532

Yuliya L. Melyanovskaya - Research Fellow, Scientific and Clinical Department of Cystic Fibrosis.

1 Moskvorech'e ul., Moscow, 115522.

Russian Federation

N. V. Bulatenko

Research Centre for Medical Genetics

Email: bnv695@gmail.com

Nataliya V. Bulatenko - Junior Research Fellow, Laboratory of Stem Cell Genetics.

1 Moskvorech'e ul., Moscow, 115522.

Russian Federation

T. B. Bukharova

Research Centre for Medical Genetics

Email: bukharova-rmt@yandex.ru
ORCID iD: 0000-0003-0481-256X

Tatiana B. Bukharova - PhD (in Biol.), Leading Research Fellow, Laboratory of Stem Cell Genetics.

1 Moskvorech'e ul., Moscow, 115522.

Russian Federation

D. V. Goldshtein

Research Centre for Medical Genetics

Email: dvgoldrm7@gmail.com
ORCID iD: 0000-0003-2438-1605

Dmitry V. Goldshtein - Doctor of Biol. Sci., Professor, Head of Laboratory of Stem Cell Genetics.

1 Moskvorech'e ul., Moscow, 115522.

Russian Federation

References

  1. Кондратьева ЕИ, Каширская НЮ, Капранов НИ, ред. Муковисцидоз: определение, диагностические критерии, терапия. М.: ООО «Компания БОРГЕС»; 2018.
  2. Marson FAL, Bertuzzo CS, Ribeiro JD. Classification of CFTR mutation classes. Lancet Respir Med. 2016;4(8):e37-e38. doi: 10.1016/S2213-2600(16)30188-6.
  3. De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr. 2020;109(5):893-899. doi: 10.1111/apa.15155.
  4. Cain C. Cystic fibrosis two-step. SciBX. 2012;5(8). doi: 101038/scibx2012192.
  5. Ivacaftor. Highlights of prescribing information [Internet]. Available from: https://pi.vrtx.com/files/uspi_ivacaftor.pdf.
  6. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu PA. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011;108(46):18843-18848. doi: 10.1073/pnas.1105787108.
  7. Министерство здравоохранения Российской Федерации. Клинические рекомендации «Кистозный фиброз (муковисцидоз)» [Интернет]. 2020. Доступно на: https:// bazanpa.ru/minzdrav-rossii-klinicheskie-re-komendatsii-ot01012020-h4876450/.
  8. Derichs N, Sanz J, Von Kanel T, Stolpe C, Zapf A, Tummler B, Gallati S, Ballmann M. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax. 2010;65(7):594-599. doi: 10.1136/thx.2009.125088.
  9. Мельяновская ЮЛ, Кондратьева ЕИ, Куцев СИ. Определение референтных значений для метода определения разности кишечных потенциалов в Российской Федерации. Медицинский вестник Северного Кавказа. 2020;15(2):162-166. doi: 10.14300/ mnnc.2020.15039.
  10. Dekkers JF, van der Ent CK, Beekman JM. Novel opportunities for CFTR-targeting drug development using organoids. Rare Dis. 2013;1:e27112. doi: 10.4161/rdis.27112.
  11. Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, Bronsveld I, van de Graaf EA, Nieuwenhuis EE, Houwen RH, Vleggaar FP, Escher JC, de Rijke YB, Majoor CJ, Heijerman HG, de Winter-de Groot KM, Clevers H, van der Ent CK, Beekman JM. Characterizing responses to CFTR-modu-lating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med. 2016;8(344):344ra84. doi: 10.1126/scitranslmed.aad8278.
  12. Boj SF, Vonk AM, Statia M, Su J, Vries RR, Beekman JM, Clevers H. Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients. J Vis Exp. 2017;(120):55159. doi: 10.3791/55159.
  13. Vonk AM, van Mourik P, Ramalho AS, Silva IAL, Statia M, Kruisselbrink E, Suen SWF, Dekkers JF, Vleggaar FP, Houwen RHJ, Mullenders J, Boj SF, Vries R, Amaral MD, de Boeck K, van der Ent CK, Beekman JM. Protocol for Application, Standardization and Validation of the Forskolin-In-duced Swelling Assay in Cystic Fibrosis Human Colon Organoids. STAR Protoc. 2020;1(1): 100019. doi: 10.1016/j.xpro.2020.100019.
  14. Кондратьева ЕИ, Мельяновская ЮЛ, Ефремова АС, Булатенко НВ, Бухарова ТБ, Гольдштейн ДВ, Зодьбинова АЭ, Никонова ВС, Жекайте ЕК, Каширская НЮ, Мелконян ГГ, Одинаева НД, Куцев СИ. Опыт применения методов оценки функциональности анионного канала CFTR у пациентов с установленным и предполагаемым диагнозом муковисцидоза. Сибирское медицинское обозрение. 2019;2(116):60-69. doi: 10.20333/2500136-2019-2-60-69.
  15. Амелина ЕЛ, Каширская НЮ, Кондратьева ЕИ, Красовский СА, Старинова МА, Воронкова АЮ, ред. Регистр больных муковисцидозом в Российской Федерации. 2018 год. М.: Медпрактика-М; 2020. 68 с.
  16. Zolin A, Orenti A, van Rens J, Fox A, Krasnyk M, Cosgriff R, Hatziagorou E, Jung A, MeiZahav M, Storms V. ECFS Patient Registry Annual Data Report 2018 [Internet]. 2020. Available from: https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Report_2018_v1.4.pdf.
  17. Dekkers JF, Gogorza Gondra RA, Kruissel-brink E, Vonk AM, Janssens HM, de Winter-de Groot KM, van der Ent CK, Beekman JM. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Eur Respir J. 2016;48(2):451-458. doi: 10.1183/13993003.01192-2015.

Supplementary files

There are no supplementary files to display.


Copyright (c) 2021 Kondratyeva E.I., Odinaeva N.D., Sherman V.D., Efremova A.S., Melyanovskaya Y.L., Bulatenko N.V., Bukharova T.B., Goldshtein D.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies